Free tool
FAERS Monitor: Rowasa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019618 or its brand name (Rowasa, Mesalamine). Reports on generic versions are filed under their own applications.
Reports
28,157
Serious
24,946
89% of reports
Hospitalization
9,525
Death reported
1,988
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use6,489
- colitis ulcerative4,631
- drug ineffective4,453
- condition aggravated3,401
- diarrhoea2,667
- haematochezia2,486
- fatigue2,255
- abdominal pain2,185
- weight decreased1,956
- headache1,910
- nausea1,884
- pyrexia1,834
- frequent bowel movements1,817
- intentional product use issue1,681
- inappropriate schedule of product administration1,664
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 126 |
| 2005 | 167 |
| 2006 | 120 |
| 2007 | 167 |
| 2008 | 581 |
| 2009 | 136 |
| 2010 | 281 |
| 2011 | 713 |
| 2012 | 628 |
| 2013 | 180 |
| 2014 | 226 |
| 2015 | 284 |
| 2016 | 338 |
| 2017 | 372 |
| 2018 | 596 |
| 2019 | 736 |
| 2020 | 1,165 |
| 2021 | 2,427 |
| 2022 | 4,173 |
| 2023 | 4,308 |
| 2024 | 4,045 |
| 2025 | 3,998 |
| 2026 | 2,389 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,026,002 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| colitis ulcerativeSignal | 4,631 | 86.2 | 83.8 | 350,340 |
| frequent bowel movementsSignal | 1,817 | 53.8 | 51.4 | 87,876 |
| haematocheziaSignal | 2,486 | 35.2 | 33.9 | 79,016 |
| intentional product use issueSignal | 1,681 | 14.6 | 13.9 | 20,952 |
| condition aggravatedSignal | 3,401 | 8.4 | 8.2 | 22,369 |
| abdominal painSignal | 2,185 | 7.1 | 6.8 | 11,407 |
| inappropriate schedule of product administrationSignal | 1,664 | 7.0 | 6.6 | 8,468 |
| off label useSignal | 6,489 | 5.6 | 5.5 | 25,192 |
| weight decreasedSignal | 1,956 | 5.3 | 5.0 | 6,794 |
| pyrexiaSignal | 1,834 | 4.0 | 3.8 | 4,127 |
| diarrhoeaSignal | 2,667 | 3.1 | 3.0 | 3,883 |
| drug ineffectiveSignal | 4,453 | 2.5 | 2.5 | 4,375 |
| headacheSignal | 1,910 | 2.3 | 2.2 | 1,408 |
| fatigueSignal | 2,255 | 2.2 | 2.1 | 1,466 |
| nausea | 1,884 | 1.8 | 1.7 | 667 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.